PL364833A1 - Fosforan inhibitora syntazy tlenku azotu - Google Patents
Fosforan inhibitora syntazy tlenku azotuInfo
- Publication number
- PL364833A1 PL364833A1 PL01364833A PL36483301A PL364833A1 PL 364833 A1 PL364833 A1 PL 364833A1 PL 01364833 A PL01364833 A PL 01364833A PL 36483301 A PL36483301 A PL 36483301A PL 364833 A1 PL364833 A1 PL 364833A1
- Authority
- PL
- Poland
- Prior art keywords
- nitric oxide
- phosphate salt
- oxide synthase
- synthase inhibitor
- inhibitor phosphate
- Prior art date
Links
- 229940123921 Nitric oxide synthase inhibitor Drugs 0.000 title 1
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 title 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0031179.5A GB0031179D0 (en) | 2000-12-21 | 2000-12-21 | Nitric oxide synthase inhibitors |
| PCT/GB2001/005596 WO2002050021A1 (en) | 2000-12-21 | 2001-12-17 | Nitric oxide synthase inhibitor phosphate salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL364833A1 true PL364833A1 (pl) | 2004-12-27 |
| PL207158B1 PL207158B1 (pl) | 2010-11-30 |
Family
ID=9905536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL364833A PL207158B1 (pl) | 2000-12-21 | 2001-12-17 | Związek amidynowy, środek farmaceutyczny, zastosowanie tego związku i sposób jego wytwarzania |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7317040B2 (pl) |
| EP (1) | EP1351929A1 (pl) |
| JP (1) | JP3971704B2 (pl) |
| KR (1) | KR100853049B1 (pl) |
| CN (1) | CN100369894C (pl) |
| AR (1) | AR031944A1 (pl) |
| AU (2) | AU2002222252B2 (pl) |
| BR (1) | BR0116369A (pl) |
| CA (1) | CA2432121C (pl) |
| CZ (1) | CZ301458B6 (pl) |
| GB (1) | GB0031179D0 (pl) |
| HU (1) | HUP0500736A3 (pl) |
| IL (1) | IL156305A0 (pl) |
| MX (1) | MXPA03005698A (pl) |
| NO (1) | NO328982B1 (pl) |
| NZ (1) | NZ526563A (pl) |
| PL (1) | PL207158B1 (pl) |
| WO (1) | WO2002050021A1 (pl) |
| ZA (1) | ZA200304683B (pl) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0214147D0 (en) * | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Formulations |
| ES2384969T3 (es) * | 2002-08-23 | 2012-07-16 | Pharmacia Corporation | Forma sólida cristalina del ácido (2S-5Z)-2-amino-7-(etanimidoilamino)-2-metilhept-5-enoico |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| JP5281291B2 (ja) | 2005-01-10 | 2013-09-04 | グラクソ グループ リミテッド | 新規化合物 |
| UY29439A1 (es) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| MY145281A (en) | 2005-03-25 | 2012-01-13 | Glaxo Group Ltd | Novel compounds |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| PE20071068A1 (es) | 2005-12-20 | 2007-12-13 | Glaxo Group Ltd | Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3 |
| EA200801997A1 (ru) | 2006-04-20 | 2009-04-28 | Глаксо Груп Лимитед | Новые соединения |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| NZ574533A (en) | 2006-08-01 | 2011-05-27 | Glaxo Group Ltd | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| US20080114021A1 (en) * | 2006-11-09 | 2008-05-15 | University Of Maryland Baltimore | Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| JP5791500B2 (ja) | 2008-05-23 | 2015-10-07 | パンミラ ファーマシューティカルズ,エルエルシー. | 5−リポキシゲナーゼ活性化タンパク質阻害剤 |
| EP2280946B1 (en) | 2008-06-05 | 2016-02-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
| WO2009147190A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
| JP2012520845A (ja) | 2009-03-17 | 2012-09-10 | グラクソ グループ リミテッド | Itk阻害剤として使用されるピリミジン誘導体 |
| US20120029054A1 (en) | 2009-03-19 | 2012-02-02 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA) |
| JP2012520683A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた結合組織増殖因子(CTGF)遺伝子発現のRNA干渉媒介性阻害 |
| US20120035247A1 (en) | 2009-03-19 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| AU2010226604A1 (en) | 2009-03-19 | 2011-10-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing |
| WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP2411517A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
| US20120022142A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| US8399436B2 (en) | 2009-04-24 | 2013-03-19 | Glaxo Group Limited | N-pyrazolyl carboxamides as CRAC channel inhibitors |
| WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| RS53830B1 (sr) | 2009-04-30 | 2015-06-30 | Glaxo Group Limited | Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze |
| EP2507231A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
| WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
| WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| US20120272951A1 (en) | 2009-12-16 | 2012-11-01 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
| TWI375671B (en) * | 2010-03-01 | 2012-11-01 | Univ China Medical | Pharmaceutical compositions containing brazilin for inhibiting expression of cytokines of t helper cell type ii and/or inhibiting expression of chemokines and uses of the same |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| HRP20151017T1 (hr) | 2010-09-08 | 2015-10-23 | Glaxosmithkline Intellectual Property Development Limited | Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida |
| EP2613781B1 (en) | 2010-09-08 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| JP5795643B2 (ja) | 2010-10-21 | 2015-10-14 | グラクソ グループ リミテッドGlaxo Group Limited | アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物 |
| WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| JP2012140390A (ja) * | 2011-01-06 | 2012-07-26 | Sumitomo Chemical Co Ltd | α−アミノ−γ−ブチロラクトンの製造方法 |
| US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| CN102344397B (zh) * | 2011-08-23 | 2013-09-04 | 浙江升华拜克生物股份有限公司 | 一种伐奈莫林盐酸盐的提纯方法 |
| KR20160060100A (ko) | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| US9399637B2 (en) | 2014-03-28 | 2016-07-26 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
| EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
| WO2017214159A1 (en) * | 2016-06-06 | 2017-12-14 | The Regents Of The University Of California | A host cell modified to produce lactams |
| WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| EP3740468B1 (en) | 2018-01-20 | 2025-12-31 | Sunshine Lake Pharma Co., Ltd. | Substituted Aminopyrimidine Compounds and Methods of Use |
| CN109369432B (zh) * | 2018-11-02 | 2021-06-25 | 永农生物科学有限公司 | (s)-4-氯-2-氨基丁酸酯的制备方法 |
| CA3173172A1 (en) | 2020-03-26 | 2021-09-30 | Christopher D. Kane | Cathepsin inhibitors for preventing or treating viral infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0957087B1 (en) * | 1994-06-15 | 2002-12-04 | The Wellcome Foundation Limited | Intermediates useful in the preparation of enzyme inhibitors |
| US6156341A (en) * | 1994-07-04 | 2000-12-05 | Schering Aktiensgesellschaft | Low-dosed steroid tablets that contain gallic acid ester as an antioxidant, process for production, and use |
| MY117948A (en) * | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| OA11901A (en) | 1998-03-11 | 2006-04-10 | Searle & Co | Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors. |
| GB9810299D0 (en) * | 1998-05-15 | 1998-07-15 | Glaxo Group Ltd | Use of nitric oxide synthase inhibitors |
-
2000
- 2000-12-21 GB GBGB0031179.5A patent/GB0031179D0/en not_active Ceased
-
2001
- 2001-12-17 WO PCT/GB2001/005596 patent/WO2002050021A1/en not_active Ceased
- 2001-12-17 JP JP2002551520A patent/JP3971704B2/ja not_active Expired - Fee Related
- 2001-12-17 CN CNB018227066A patent/CN100369894C/zh not_active Expired - Fee Related
- 2001-12-17 CZ CZ20031744A patent/CZ301458B6/cs not_active IP Right Cessation
- 2001-12-17 PL PL364833A patent/PL207158B1/pl not_active IP Right Cessation
- 2001-12-17 AU AU2002222252A patent/AU2002222252B2/en not_active Ceased
- 2001-12-17 AU AU2225202A patent/AU2225202A/xx active Pending
- 2001-12-17 CA CA002432121A patent/CA2432121C/en not_active Expired - Fee Related
- 2001-12-17 MX MXPA03005698A patent/MXPA03005698A/es active IP Right Grant
- 2001-12-17 KR KR1020037008395A patent/KR100853049B1/ko not_active Expired - Fee Related
- 2001-12-17 US US10/451,299 patent/US7317040B2/en not_active Expired - Fee Related
- 2001-12-17 EP EP01271352A patent/EP1351929A1/en not_active Withdrawn
- 2001-12-17 NZ NZ526563A patent/NZ526563A/en unknown
- 2001-12-17 IL IL15630501A patent/IL156305A0/xx unknown
- 2001-12-17 BR BR0116369-8A patent/BR0116369A/pt not_active Application Discontinuation
- 2001-12-17 HU HU0500736A patent/HUP0500736A3/hu unknown
- 2001-12-19 AR ARP010105911A patent/AR031944A1/es unknown
-
2003
- 2003-06-17 ZA ZA200304683A patent/ZA200304683B/en unknown
- 2003-06-20 NO NO20032835A patent/NO328982B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2432121C (en) | 2009-12-01 |
| NZ526563A (en) | 2004-11-26 |
| HUP0500736A2 (hu) | 2005-11-28 |
| MXPA03005698A (es) | 2003-10-06 |
| CZ301458B6 (cs) | 2010-03-10 |
| EP1351929A1 (en) | 2003-10-15 |
| AU2225202A (en) | 2002-07-01 |
| AU2002222252B2 (en) | 2005-02-24 |
| WO2002050021A1 (en) | 2002-06-27 |
| US7317040B2 (en) | 2008-01-08 |
| ZA200304683B (en) | 2004-09-17 |
| JP3971704B2 (ja) | 2007-09-05 |
| IL156305A0 (en) | 2004-01-04 |
| BR0116369A (pt) | 2003-10-28 |
| AR031944A1 (es) | 2003-10-08 |
| KR100853049B1 (ko) | 2008-08-19 |
| HUP0500736A3 (en) | 2009-12-28 |
| GB0031179D0 (en) | 2001-01-31 |
| CA2432121A1 (en) | 2002-06-27 |
| JP2004516278A (ja) | 2004-06-03 |
| PL207158B1 (pl) | 2010-11-30 |
| NO20032835D0 (no) | 2003-06-20 |
| NO328982B1 (no) | 2010-07-05 |
| KR20030066737A (ko) | 2003-08-09 |
| NO20032835L (no) | 2003-08-15 |
| CN100369894C (zh) | 2008-02-20 |
| US20040087654A1 (en) | 2004-05-06 |
| CN1527814A (zh) | 2004-09-08 |
| CZ20031744A3 (cs) | 2004-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2225202A (en) | Nitric oxide synthase inhibitor phosphate salt | |
| AU2002222252A1 (en) | Nitric oxide synthase inhibitor phosphate salt | |
| PL344368A1 (en) | Nitric oxide synthase inhibitors | |
| AU4774501A (en) | Amidino compounds useful as nitric oxide synthase inhibitors | |
| AP9901603A0 (en) | Nitric oxide synthase inhibitors | |
| AU4430599A (en) | Inhibitors of nitric oxide synthase | |
| IL153230A0 (en) | Liposomal benzoquinazoline thymidylate synthase inhibitor formulations | |
| AU7178301A (en) | Methods for increasing nitric oxide synthase activity | |
| IL154841A0 (en) | 2-amino-2-alkyl-5- heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | |
| AP2002002593A0 (en) | Protease inhibitors | |
| IL137654A0 (en) | Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors | |
| IL152587A0 (en) | Phosphate transport inhibitors | |
| GB0018164D0 (en) | Corrosion inhibitors | |
| GB9810299D0 (en) | Use of nitric oxide synthase inhibitors | |
| GB2359500B (en) | Corrosion inhibitors | |
| AU2002350575A1 (en) | Selective neuronal nitric oxide synthase inhibitors | |
| HK1061402A (en) | Nitric oxide synthase inhibitor phosphate salt | |
| GB0031177D0 (en) | Nitric oxide synthase inhibitors | |
| HRP980381B1 (en) | Nitric oxide synthase inhibitors | |
| SI1084104T1 (en) | Nitric oxide synthase inhibitors | |
| SI0958277T1 (en) | Nitric oxide synthase inhibitors | |
| GB0016172D0 (en) | Microencapsulated nitric oxide synthase source | |
| PL338655A1 (en) | Anticorrosive agent | |
| GB0100485D0 (en) | Corrosion inhibitors | |
| GB0029733D0 (en) | Inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RECP | Rectifications of patent specification | ||
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20121217 |